• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

SpyGlass Pharma unveils 1-year data of drug delivery platform implanted during routine cataract surgery in patients diagnosed with glaucoma

News
Article

One year after implantation, the enduring IOP reduction remained consistent across all 3 dose strengths.

(Image Credit: AdobeStock/ipopba)

(Image Credit: AdobeStock/ipopba)

SpyGlass Pharma announced 1-year follow-up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ in IOL-based drug delivery platform with bimatoprost at the time of cataract surgery.

These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, held from April 5 to 8 at the Boston Convention and Exhibition Center in Boston.

The company noted in a news release that 1 year after implantation, the enduring IOP reduction remained consistent across all 3 dose strengths, achieving a mean pressure reduction of 44.6% at month 12 compared to pre-operative washed-out baseline levels. All patients sustained more than a 20% IOP reduction from baseline and IOPs of < 18 mm Hg through month 12. Additionally, 100% of patients remain off topical IOP-lowering drops. The SpyGlass platform was well tolerated and there were no adverse events related to the product.1

The clinical results, 1 year after implantation, continue to be highly encouraging for patients living with glaucoma, said Margot Goodkin, chief medical officer, SpyGlass Pharma.

“Bimatoprost has provided patients across the globe with safe, highly effective IOP-lowering over 2 decades,” Goodkin noted in the news release.

Patrick Mooney, CEO, SpyGlass Pharma, pointed out in the news release that the technology has the potential to change the paradigm and improve care for glaucoma patients undergoing routine cataract surgery.

“There are nearly 5 million annual cataract procedures in the United States, approximately 20% of them are performed in patients with glaucoma or ocular hypertension,” Mooney said in a news release. “The unmet need is significant, and SpyGlass is committed to delivering safe and effective therapeutics via proven implantation techniques to improve the lives of patients living with chronic eye conditions. The compelling clinical data released this week suggest we are on track to bringing our innovative platform to patients.”

According to the company, its drug delivery platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues. Patients will continue to be followed over time and the Company plans to share longer-term data in the coming months.1

SpyGlass is currently enrolling patients in a Phase I/II study in the US to investigate the safety and efficacy of its platform in a larger patient pool. SpyGlass looks forward to working closely with the FDA to advance the program to commercial approval.

Reference:
  1. Inc SP. SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma. GlobeNewswire News Room. Published April 2, 2024. Accessed April 2, 2024. https://www.globenewswire.com/news-release/2024/04/02/2855881/0/en/SpyGlass-Pharma-Unveils-Compelling-1-Year-Data-of-Its-Innovative-Drug-Delivery-Platform-Implanted-During-Routine-Cataract-Surgery-in-Eyes-with-Glaucoma.html
Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.